Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Table 2 The detail treatment and therapeutic evaluation of 8 patients

ID	PD 1 inhibitors	SBRT		Therapeutic evaluation
ID	PD 1 inhibitors	Dose	Radiation sites	PD-1inhibitor alone	Radiated lesions	Non-Radiated lesions
1	Nivolumab (5 cycles)	25 Gy/5Fx	Progressive lesions	PD	PR	PD
2	Pembroizumab (6 cycles)	30 Gy/6Fx	All visible lesions	PD	CR	NA
3	Nivolumab (5 cycles)	30 Gy/6Fx	Progressive lesions	PD	CR	Unevaluable
4	Nivolumab (14 cycles)	36 Gy/6Fx	Main lesions	SD	PR	SD
5	Nivolumab (11 cycles)	30 Gy/6Fx	Main lesions	SD	PR	SD
6	Nivolumab (6 cycles)	30 Gy/6Fx	All visible lesions	PD	CR	NA
7	Nivolumab (6 cycles)	No	NA	CR	NA	NA
8	Nivolumab (9 cycles)	30 Gy/6Fx	Progressive lesions	PD	PR	Unevaluable

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NA: not assessed

ISSN: 1748-717X